The drought in New Chemical Entities (NCEs) in the marketplace is the result of many organizations having developed specific molecular-targeted agents that subsequently failed in the clinic. These failures can be attributed to traditional methods for evaluating compound recommendations for clinical trial and the inability to bring new technologies to bear at the pre-clinical stage. At Progenra we believe that greater scrutiny of compounds at the pre-clinical stage will significantly increase clinical success rates.
Read More

Progenra is developing compounds targeting the ubiquitin pathway for in house clinical development. In addition, a number of compounds at different stages of development, which address various therapeutic areas and novel molecular targets, are available for co-development through a partnership.
Read More